March 28 (Reuters) - Replicel Life Sciences Inc RP.V :
* Replicel's successful rct-01 tendon repair clinical trial shows signs of healing chronic tendon problems
* Replicel Life Sciences-first-in-human clinical study meets primary endpoint demonstrating product safety, clinical potential for tendon regeneration, healing
* Replicel Life Sciences Inc - clinical trial met its goal of establishing a complete safety profile at 6 months
* Replicel Life Sciences Inc - clinical trial showed no serious adverse events related to study treatment or injection procedure Source text for Eikon: ID:nCNWRy6Zqa Further company coverage: RP.V